Search

Bromfenac versus betamethasone in diabetic macular oedema

This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...

The compendium to clinical evidence in DMO treatment

This review article summarises the current evidence base in the treatment options for diabetic macular oedema (DMO). The authors have included many real-world data studies that provided valuable insights into the optimal management of DMO. The authors argue that these...

Comprehensive review of inherited retinal diseases

The authors offer an up-to-date review of inherited retinal diseases (IRDs). In each section the authors discuss the molecular basis of disease, genotype and clinical manifestation. They also discuss the investigation findings and current evidence in the treatment of the...

OCT measurements in neurodevelopmental conditions

The authors aimed to investigate what changes occur in the retinal nerve fibre layer (RNFL), ganglion cell layer (GCL) and macula when specific learning disorder (SLD) comorbidity is added to attention deficit hyperactivity disorder (ADHD). They compared measures in three...

Long-term treatment for diabetic macular oedema

The authors set out to characterise anti-VEGF treatment patterns and long-term outcomes in patients with diabetic macular oedema. A retrospective analysis of over 190 thousand patients on the Intelligent Research in Sight registry was performed. Of these, 1236 eyes have...

Treatment efficacy of stage 4 ROP

This study aimed to determine the efficacy of combined vitrectomy and anti-VEGF injection for advanced stage 4 ROP with extensive neovascular proliferation (NF). The study included nine infants; six bilateral and three unilateral. Seven were female and the mean gestational...